Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 7/2006

01-07-2006 | Original Article

Causes of fever in cancer patients (prospective study over 477 episodes)

Authors: E. Toussaint, E. Bahel-Ball, M. Vekemans, A. Georgala, L. Al-Hakak, M. Paesmans, M. Aoun

Published in: Supportive Care in Cancer | Issue 7/2006

Login to get access

Abstract

Goals of work

The aim of this study was to determine the causes of fever among cancer patients.

Methods

All febrile cancer patients were followed up prospectively. Clinical, microbiological and radiological documentations were performed. Aetiologies of fever, type of tumour, site of infection, type of microorganism and outcome were assessed and compared between neutropenics and non-neutropenics.

Results

Four hundred and seventy-seven episodes were evaluated. Infection, non-infectious causes and fever of unknown origin represented 67, 23 and 10%, respectively. The respiratory tract is the most frequently involved site in infection (29%), and in microbiologically documented infections, Gram-negative bacilli were predominant. The tumour itself (27%) or an invasive procedure (17%) were the main causes of non-infectious febrile episodes. Mortality from infection was higher among non-neutropenic (11.1%) than neutropenic patients (4.3%).

Conclusion

Fever in cancer patients remains a challenge, and the differentiation between infectious and non-infectious causes at onset of fever is very difficult. Despite all the prophylactic measures, infection is still the principal cause. However, the infection-related mortality is low either in neutropenic or non-neutropenic patients.
Literature
1.
Akova M, Paesmans M, Calandra T et al (2005) A European organization for research and treatment of cancer-international antimicrobial therapy group study of secondary infections in febrile, neutropenic patients with cancer. Clin Infect Dis 40:239–245CrossRefPubMed
2.
Circiumaru B, Baldock G, Cohen J (1999) A prospective study of fever in the intensive care unit. Intensive Care Med 25:648–651CrossRefPubMed
3.
Cometta A, Calandra T, Gaya H et al (1996) Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 40:1108–1115PubMed
4.
Cometta A, Kern WV, De Bock R et al (2003) Vancomcyin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 37:382–389CrossRefPubMed
5.
Dinarello CA (1996) Thermoregulation and the pathogenesis of fever. Infect Dis Clin North Am 10:433–449CrossRefPubMed
6.
7.
Ezidiegwu CN, Lauenstein KJ, Rosales LG et al (2004) Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Pathol Lab Med 128:991–995PubMed
8.
Fanning J, Neuhoff RA, Brewer JE et al (1998) Frequency and yield of postoperative fever evaluation. Infect Dis Obstet Gynecol 6:252–255CrossRefPubMed
9.
Garcia-Suarez J, Krsnik I, Reyes E et al (2003) Elderly haematological patients with chemotherapy-induced febrile neutropenia have similar rates of infection and outcome of younger adults: a prospective study of risk-adapted therapy. Br J Haematol 120:209–216CrossRefPubMed
10.
Hann I, Viscoli C, Paesmans M et al (1997) A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 99:580–588CrossRefPubMed
11.
Henderson RA, Pinder L (1990) Acute transfusion reactions. N Z Med J 103:509–511PubMed
12.
Hughes W, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751CrossRefPubMed
13.
Klastersky J (1994) Non-infectious causes of fever in cancer patients. In: Glauser MP, Calandra T (eds) International practice and research on infections in immunocompromised oncological patients, vol. 1. Baillière Tindall, London, pp 439–454
14.
Klastersky J (1998) Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother 41(suppl. D):13–24CrossRefPubMed
15.
Klastersky J, Weerts D, Hensgens C et al (1973) Fever of unexplained origin in patients with cancer. Eur J Cancer 9:649–656PubMed
16.
Le Roux P, de Blic J, Albertini M et al (2004) Flexible bronchoscopy in children. Experience at French centers of pediatric pneumology. Rev Mal Respir 21:1098–1106PubMed
17.
Luft FC, Rissing JP, White A et al (1976) Infections of neoplasm as causes of prolonged fever in cancer patients. Am J Med Sci 272:65–74PubMedCrossRef
18.
Mackowiak PA, Le Maistre CF (1987) Drug fever: a critical appraisal of conventional concepts. An analysis of 51 episodes in two Dallas hospitals and 97 episodes reported in the English literature. Ann Intern Med 106:728–733PubMed
19.
McGeer A, Feld R (1994) Epidemiology of infection in immunocompromised oncological patients. In: Glauser MP, Calandra T (eds) International practice and research on infections in immunocompromised oncological patients, vol. 1. Baillière Tindall, London, pp 415–438
20.
Mulabecirovic A, Gaulhofer P, Auner HW et al (2004) Pulmonary infiltrates in patients with haematological malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis. Ann Hematol 83:420–422CrossRefPubMed
21.
Pizzo PA, Robichaud KJ, Wesley R et al (1982) Fever and pediatric and young adult patient with cancer. A prospective study of 1,001 episodes. Medicine 61:153–165PubMedCrossRef
22.
Rossi C, Klastersky J (1996) Initial empirical antibiotic therapy for neutropenic fever analysis of the cause of death. Support Care Cancer 4:207–212CrossRefPubMed
23.
Rubio M, Palau L, Vivas JR et al (1994) Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 15:101–104PubMedCrossRef
24.
Scharfe T, Alken P, Muller ST et al (1990) Percutaneous litholapaxy. Indications and limitations of the technique in complex nephrolithiasis. Arch Esp Urol 43:311–318PubMed
25.
Velasco E, Byington R, Martins CS et al (2004) Bloodstream infection surveillance in a cancer centre: a prospective look at clinical microbiology aspects. Clin Microbiol Infect 10:542–549CrossRefPubMed
26.
Viscoli C (1998) The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 41 (suppl. D.):65–80CrossRefPubMed
27.
Viscoli C, Bruzzi P, Castagnola E et al (1994) Factors associated with bacteraemia in febrile, granulocytopenic cancer patients. The International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer 30A:430–437CrossRefPubMed
28.
Zihlif M, Khanchandani G, Ahmed HP et al (2005) Surgical lung biopsy in patient with hematological malignancy or hematopoietic stem cell transplantation and unexplained pulmonary infiltrates: improved outcome with specific diagnosis. Am J Hematol 78:94–99CrossRefPubMed
Metadata
Title
Causes of fever in cancer patients (prospective study over 477 episodes)
Authors
E. Toussaint
E. Bahel-Ball
M. Vekemans
A. Georgala
L. Al-Hakak
M. Paesmans
M. Aoun
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 7/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0898-0

Other articles of this Issue 7/2006

Supportive Care in Cancer 7/2006 Go to the issue

Review Article

A meta-analysis of exercise interventions among people treated for cancer

Original Article

Utilising handheld computers to monitor and support patients receiving chemotherapy: results of a UK-based feasibility study

Forthcoming Meetings

Forthcoming Meetings

Original Article

Who helps the leaders? Difficulties experienced by cancer support group leaders

Review Article

Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage

Editorial

The silent symptom early satiety: a forerunner of distinct phenotypes of anorexia/cachexia syndromes
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits